



Q2 Metformin and caloric restriction induce an AMPK-dependent 2 restoration of mitochondrial dysfunction in fibroblasts from 3 Fibromyalgia patients

Q3 Elísabet Alcocer-Gómez^{a,b}, Juan Garrido-Maraver^b, Pedro Bullón^{a,c}, Fabiola Marín-Aguilar^a, David Cotán^b,
5 Angel M. Carrión^d, José Miguel Alvarez-Suarez^{e,f,g}, Francesca Giampieri^h, José Antonio Sánchez-Alcazar^b,
6 Maurizio Battino^{e,i}, Mario D. Cordero^{a,*}

7 ^a Research Laboratory, Oral Medicine Department, Universidad de Sevilla, Sevilla, Spain

8 ^b Centro Andaluz de Biología del Desarrollo (CABD), Universidad Pablo de Olavide-CSIC-Junta de Andalucía and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII,
9 41013 Sevilla, Spain

10 ^c Dept. of Periodontology, Dental School, University of Sevilla, Spain

11 ^d División de Neurociencias, Universidad Pablo de Olavide de Sevilla, Carretera de Utrera Km. 1, 41013 Sevilla, Spain

12 ^e Dipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche (DISCO)-Sez. Biochimica, Facoltà di Medicina, Università Politecnica delle Marche, Ancona 60131, Italy

13 ^f Area de Nutrición y Salud, Universidad Internacional Iberoamericana (UNINI), Campeche C.P.24040, Mexico

14 ^g Facultad de Ciencias de la Salud, Universidad Nacional de Chimborazo, Riobamba, Ecuador

15 ^h Dipartimento di Scienze Agrarie, Alimentari e Ambientali (D3A), Università Politecnica delle Marche, Via Ranieri 65, Ancona 60131, Italy

16 ⁱ Director Centre for Nutrition & Health, Universidad Europea del Atlántico (UEA), Santander 39011, Spain

17 A R T I C L E I N F O

18 Article history:

19 Received 20 December 2014

20 Received in revised form 4 March 2015

21 Accepted 7 March 2015

22 Available online xxxx

23 Keywords:

24 Fibromyalgia

25 AMPK

26 Mitochondria

27 Oxidative stress

28 Metformin

29 Caloric restriction

A B S T R A C T

Impaired AMPK is associated with a wide spectrum of clinical and pathological conditions, ranging from obesity, 30 altered responses to exercise or metabolic syndrome, to inflammation, disturbed mitochondrial biogenesis and 31 defective response to energy stress. Fibromyalgia (FM) is a world-wide diffused musculoskeletal chronic pain 32 condition that affects up to 5% of the general population and comprises all the above mentioned pathophysiological 33 states. Here, we tested the involvement of AMPK activation in fibroblasts derived from FM patients. AMPK 34 was not phosphorylated in fibroblasts from FM patients and was associated with decreased mitochondrial 35 biogenesis, reduced oxygen consumption, decreased antioxidant enzymes expression levels and mitochondrial 36 dysfunction. However, mtDNA sequencing analysis did not show any important alterations which could justify 37 the mitochondrial defects. AMPK activation in FM fibroblast was impaired in response to moderate oxidative 38 stress. In contrast, AMPK activation by metformin or incubation with serum from caloric restricted mice 39 improved the response to moderate oxidative stress and mitochondrial metabolism in FM fibroblasts. These re- 40 sults suggest that AMPK plays an essential role in FM pathophysiology and could represent the basis for a valuable 41 new therapeutic target/strategy. Furthermore, both metformin and caloric restriction could be an interesting 42 therapeutic approach in FM. 43

© 2015 Elsevier B.V. All rights reserved.

46 1. Introduction

47
48 Mitochondria are essential organelles present in virtually all eukaryotic cells. One of the primary functions of mitochondria is ATP production 49 via the oxidative phosphorylation (OXPHOS) pathway. Moreover, they play crucial roles in many other metabolic, regulatory and developmental processes [1]. The involvement of mitochondria in a variety of pathological mechanisms has been partially ascribed to their central role in reactive oxygen species (ROS) production and to the damaging

50 effect mediated by ROS themselves on the same organelles [2]. In eu- 51 karyotic cells, mitochondrial biogenesis is triggered through modulation 52 of the ATP/ADP ratio, activation of adenosine monophosphate 53 activated protein kinase (AMPK) and the subsequent expression of peroxisomal proliferator activator receptor γ co-activator 1 α (PGC-1 α) and 54 nuclear respiratory factor-1 (NRF1) transcription factors. The AMPK cascade is one of the intracellular pathways that have evolved to ensure 55 that energy homeostasis is maintained even under pathological conditions or stress [3]. AMPK has also been involved in the cellular defense 56 against oxidative stress damage induced by mitochondrial ROS through the increase of MnSOD and catalase expression levels [4]. 57

58 Fibromyalgia (FM) is a common chronic pain syndrome accompanied by other symptoms such as fatigue, headache, sleep disturbances, 59 and depression. Despite the fact that it affects up to 5% of the general 60 population, the pathophysiology of FM remains unclear. 61

* Corresponding author at: Research Laboratory, Oral Medicine Department, Universidad de Sevilla, C/Avicena s/n, 41009 Sevilla, Spain. Tel.: +34 954 481120; fax: +34 954 486784.

E-mail address: mdcormor@us.es (M.D. Cordero).

population worldwide, its pathogenic mechanism remains elusive. Because not all FM patients have a mitochondrial dysfunction, it has recently been hypothesized that oxidative stress and mitochondrial dysfunction may be important events in pathogenesis of a subgroup of FM patients [5–9]. There is evidence supporting this hypothesis, and thus, reduced mitochondrial mass and impaired bioenergetics have been described in blood cells derived from FM patients [8–10]. Furthermore, different antioxidant enzymes have been observed to be drastically reduced in FM patients [5–7,9,11]. Recently, we have also found reduced AMPK gene expression levels in blood mononuclear cells (BMCs) from FM patients [9].

As AMPK has a central regulatory role in cell metabolism, mitochondrial biogenesis and oxidative stress response, we evaluate if AMPK down-regulation could be at least in part responsible for the impaired oxidative stress response and mitochondrial dysfunction observed in FM. Here, we assessed this hypothesis in cultured skin fibroblasts from patients enrolled in a trial concerning the study of inflammation and mitochondrial dysfunction in BMCs (all patients had mitochondrial dysfunction in BMCs) [8].

2. Material and methods

2.1. Ethical statements

The approval of the ethical committee of the University of Seville was obtained, according to the principles of the Declaration of Helsinki and all the International Conferences on Harmonization and Good Clinical Practice Guidelines. All participants in the study gave their written informed consent before initiating it.

2.2. Patients

The inclusion criterion was Fibromyalgia, based on current ACR diagnostic criteria [9], and diagnosed 2 to 3 years previously. The clinical characteristics of each group are shown in Supplementary Table 1. Exclusion criteria were: acute infectious disease within the previous 3 weeks; past or present neurological, psychiatric, metabolic, autoimmune, allergy-related, dermal or chronic inflammatory disease; undesired habits (e.g., smoking and alcohol); medical conditions that required glucocorticoid treatment, analgesics or antidepressant drugs; past or current substance abuse or dependence; pregnancy or current breastfeeding. Three FM female patients and two healthy female volunteers matched for age range, gender, ethnicity and demographic features (completion of at least 9 years of education and member of the middle socioeconomic class), were included in the study. Healthy controls had no signs or symptoms of FM and had not taken any medication for at least 3 weeks prior to commencing the study. None of the patients or controls had taken any drug or vitamin/nutritional supplements during the 3 weeks prior to blood sample collection. All patients and controls followed a standard balanced diet (carbohydrate 50–60%, protein 10–20% and fat 20–30%) for 3 weeks prior to blood collection, as established by a diet program. Clinical data were obtained from a physical examination and subjects were evaluated using the Fibromyalgia Impact Questionnaire (FIQ), the visual analogues scale (VAS) and depression with the Beck Depression Inventory (BDI). Tender points were identified by digital pressure at the 18 locations recommended by ACR which included a minimum of 11 out of 18. Coagulated blood samples were collected from patients and controls after 12 h fasting, centrifuged at 3800 ×g for 5 min, and the serum was stored at –80 °C until testing. Serum biochemical parameters were assayed by routine analytical methods. Routine laboratory test yielded normal results for glucose, uric acid, creatine kinase, aspartate aminotransferase, alanine aminotransferase, cholesterol, and triglycerides (Supplementary Table 2).

2.3. Reagents

Trypsin and metformin were purchased from Sigma Chemical Co., (St. Louis, Missouri). Monoclonal Antibodies specific for mitochondrial respiratory chain complex subunits [Anti-human Complex I (39 kDa subunit), Complex II (30 kDa subunit I), Complex III (Core 1 subunit and Complex IV (COX II)], Mitosox™, PicoGreen, and Hoechst 3342, were purchased from Invitrogen/Molecular Probes (Eugene, Oregon). Anti-cytochrome c antibodies were purchased from PharMingen (BD Bioscience, San Jose, California). Anti-GAPDH monoclonal antibody, clone 6C5, was purchased from Research Diagnostic, Inc., (Flanders, New Jersey). Complex I 8 kDa subunit and Complex II 70 kDa subunit, anti-PGC1- α and OGG-1 antibodies were from Abcam (Cambridge, UK); anti-AMPK-p antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); and MnSOD antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). A cocktail of protease inhibitors (complete cocktail) was purchased from Boehringer Mannheim (Indianapolis, IN). The ImmunStar HRP substrate kit was from Bio-Rad Laboratories Inc. (Hercules, CA).

2.4. Caloric restriction assay

For all experiments, only male mice were used. Eight-week-old male C57/BL6/J mice weighing 25–30 g were maintained on a 12 h light/dark cycle. All studies were performed in accordance with the European Union guidelines (86/609/EU) and Spanish regulations for the use of laboratory animals in chronic experiments (BOE 67/8509-12, 1988). All experiments were approved by the local institutional animal care committee. Calorie restriction (CR) regimen was progressively implemented: it was initiated with 10% restriction diet during the first week, followed by 20 and 30% during the second and third weeks, respectively, and maintained at 30% until the end of treatment. After testing, mice were sacrificed by decapitation. Blood samples were collected frozen at –80 °C. In several experiments, fibroblasts were cultured using 10% mice serum fed *ad libitum* (AL) or CR. Cells were incubated at 37 °C in a 5% CO₂ atmosphere. Serum was heat activated for 30 min at 55 °C.

2.5. Behavioral assays

Behavioral analyses were performed in a testing room with homogeneous noise and light levels. The testing apparatus was cleaned with 70% ethanol (Panreac Química S.A.U.) between trials to eliminate any influence of animal odor on the exploratory behavior.

2.6. Pain assay

For the hot-plate test, a glass cylinder (16 cm high, 16 cm in diameter) was used to constrain the mice to the heated surface of the plate. The plate surface was maintained at 50–55 ± 0.5 °C and the latency to paw-licking was measured, with a cut-off of 30 s.

2.7. Fibroblast cultures

Control fibroblasts were human primary fibroblasts from healthy volunteers. Samples from patients and controls were obtained according to the Helsinki Declarations of 1964, as revised in 2001. Fibroblasts were cultured in DMEM media (4500 mg/L glucose, L-glutamine, piruvate), (Gibco, Invitrogen, Eugene, OR, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen, Eugene, OR, USA) and antibiotics (Sigma Chemical Co., St. Louis, MO, USA). Cells were incubated at 37 °C in a 5% CO₂ atmosphere.

183	2.8. Treatment		
184	2 mM metformin (Sigma Aldrich) and/or 100 μ M of H ₂ O ₂ at 48 h		
185	were used for <i>in vitro</i> experiments.		
186	2.9. Mitochondrial respiratory chain enzyme activities		
187	Activities of NADH:coenzyme Q1 oxidoreductase (complex I),		
188	succinate deshydrogenase (complex II), ubiquinol:cytochrome c oxidore-		
189	ductase (complex III), cytochrome c oxidase (complex IV), NADH: cyto-		
190	chrome c reductase (complex I + III), succinate:cytochrome c reductase		
191	(complex II + complex III) and citrate synthase (CS) were determined		
192	in sonicated-permeabilized fibroblasts using spectrophotometric		
193	methods. Results are expressed as Units/CS (mean \pm SD). Proteins of		
194	fibroblast homogenates were analyzed by the Lowry procedure.		
195	2.10. Western blotting		
196	Whole cellular lysate from fibroblasts was prepared by gentle shak-		
197	ing with a buffer containing 0.9% NaCl, 20 mMTris-ClH, pH 7.6, 0.1% tri-		
198	ton X-100, 1 mM phenylmethylsulfonylfluoride and 0.01% leupeptine.		
199	Electrophoresis was carried out in a 10–15% acrylamide SDS/PAGE.		
200	Proteins were transferred to Immobilon membranes (Amersham		
201	Pharmacia, Piscataway, NJ). Mouse anti-Complex I (8 and 39 kDa sub-		
202	unit), mouse anti-complex II (30 kDa subunit I), mouse anti-Complex		
203	III (Core 1 subunit), mouse anti-complex IV (COX II), AMPK-P, PGC-1		
204	α , MnSOD, catalase and DNA repair enzyme 8-oxoguanine DNA		
205	glycolase-1 (OGG-1) antibodies were used to detect proteins by West-		
206	ern blotting. Proteins were electrophoresed, transferred to nitrocellu-		
207	lose membranes and, after blocking over night at 4 $^{\circ}$ C, incubated with		
208	the respective antibody solution, diluted at 1:1000. Membranes were		
209	then probed with their respective secondary antibody (1:2500).		
210	Immunolabeled proteins were detected by using a chemiluminescence		
211	method (Immun Star HRP substrate kit, Bio-Rad Laboratories Inc.,		
212	Hercules, CA). Protein was determined by the Bradford method.		
213	2.11. Measurement of CoQ levels		
214	CoQ levels in cultured fibroblasts were performed using a method		
215	previously described by our group [8].		
216	2.12. Antioxidant enzyme activity		
217	Catalase activity was determined in cellular lysate by monitoring		
218	H ₂ O ₂ decomposition at 240 nm [12]. SOD activity was determined on		
219	the basis of the inhibition of the formation of NADH–phenazine		
220	methosulfate–nitroblue tetrazolium formazan [13].		
221	2.13. Quantification of mtDNA		
222	Nucleic acids were extracted from fibroblasts by standard cellular		
223	lysis. The primers used were: mtF3212 (5'-CACCCAAGAACAGGGTTT		
224	GT-3') and mtR3319 (5'-TGGCCATGGGTATGTTGTAA-3') for mtDNA,		
225	and, 18S rRNA gene 18S1546F (5'-TAGAGGGACAACTGGCGTTC-3')		
226	and 18S1650R (5'-CGCTGAGCCAGTCAGTGT3') for nDNA for loading		
227	normalization. Arbitrary units were computed as the ratio between		
228	the optical density band corresponding to the mtDNA studied in the		
229	20–30th cycle and that of the nDNA in the 15th amplification cycle.		
230	One unit was considered to be the ratio corresponding to the control pa-		
231	tient. For imaging of mtDNA in living cells, control and FM fibroblasts		
232	cells were cultured in dishes with a glass bottom (MatTek Corporation,		
233	Ashland, MA) and stained with PicoGreen (3 μ M/mL) for 1 h at 37 $^{\circ}$ C.		
234	TMRM (100 nM) staining was used to visualize mitochondria.		
	2.14. Mitochondrial ROS production		235
	Mitochondrial ROS generation in BMCs and fibroblasts were	236	
	assessed by MitoSOX™ Red, a red mitochondrial superoxide indicator.	237	
	MitoSOX Red is a novel fluorogenic dye recently developed and validat-	238	
	ed for highly selective detection of superoxide in the mitochondria of	239	
	live cells. MitoSOX™ Red reagent is live-cell permeant and is rapidly	240	
	and selectively targeted to the mitochondria. Once in the mitochondria,	241	
	MitoSOX™ Red reagent is oxidized by superoxide and exhibits red	242	
	fluorescence.	243	
	2.14.1. Fluorescence microscopy		244
	Cells grown on microscope slides in 6-well plates for 24 h were incu-	245	
	bated with MitoSOX™ Red for 30 min at 37 $^{\circ}$ C, washed twice in PBS,	246	
	fixed with 4% paraformaldehyde in PBS for 0.5–1 h at room tempera-	247	
	ture, and washed twice with PBS. After that, cells were incubated for	248	
	10 min at 37 $^{\circ}$ C with anti-cytochrome c antibody (Invitrogen, Barcelona,	249	
	Spain) to label mitochondria. Slides were analyzed by immunofluores-	250	
	cence microscopy.	251	
	2.14.2. Flow cytometry		252
	Approximately 1 \times 10 ⁶ cells were incubated with 1 μ M MitoSOX™	253	
	Red for 30 min at 37 $^{\circ}$ C, washed twice with PBS, resuspended in	254	
	500 μ L of PBS and analyzed by flow cytometry in an Epics XL cytometer,	255	
	Beckman Coulter, Brea, California, USA (excitation at 510 nm and fluo-	256	
	rescence detection at 580 nm).	257	
	2.15. Oxygen consumption rate (OCR)		258
	The oxygen consumption rate (OCR) was assessed in real-time using	259	
	the 24 well Extracellular Flux Analyzer XF-24 (Seahorse Bioscience,	260	
	North Billerica, MA, USA) according to the manufacturer's protocol,	261	
	which allows measuring OCR changes after up to four sequential addi-	262	
	tions of compounds. Cells (5 \times 10 ⁴ /well) were seeded for 16 h in the	263	
	XF-24 plate before the experiment in a DMEM/10% serum medium	264	
	and then incubated for 24 h with the different compounds studied.	265	
	Before starting measurements, cells were placed in a running DMEM	266	
	medium (supplemented with 25 mM glucose, 2 mM glutamine, 1 mM	267	
	sodium Pyruvate, and without serum) and pre-incubated for 20 min	268	
	at 37 $^{\circ}$ C in the absence of CO ₂ in the XF Prep Station incubator (Seahorse	269	
	Bioscience, Billerica MA, USA). Cells were transferred to an XF-24 Extra-	270	
	cellular Flux Analyzer and after an OCR baseline measurement a profil-	271	
	ing of mitochondrial function was performed by sequential injection	272	
	of four compounds that affect bioenergetics, as follows: 55 μ L of	273	
	oligomycin (final concentration 2.5 μ g/mL) at injection in port A, 61 μ L	274	
	of 2,4-dinitrophenol (2,4-DNP) (final concentration 1 mM) at injection	275	
	in port B, and 68 μ L of antimycin/rotenone (final concentration 10 μ M/	276	
	1 μ M) at injection in port C. A minimum of five wells was utilized per	277	
	condition in any given experiment. Data are expressed as pMol of O ₂ con-	278	
	sumed per minute normalized to 1000 cells (pMol O ₂ /1000 cells/min).	279	
	2.16. Lipid peroxidation		280
	Fibroblasts were cultured on coverslips and incubated with 1 μ M	281	
	C11-Bodipy (BODIPY® 581/591 C11) for 30 min at 37 $^{\circ}$ C. Coverslips	282	
	were then rinsed with PBS and mounted onto slides as described	283	
	above for analysis with a fluorescence microscope. Fluorescent intensity	284	
	was measured using the Image J software (National Institutes of Health,	285	
	Bethesda, Maryland, USA).	286	
	Lipid peroxidation in serum from mice was detected by measuring	287	
	the concentration of TBARS in fluorescence at 532 nm (F7000, HITACHI),	288	
	using a TBARS detection kit according to the manufacturer's instruc-	289	
	tions. Absorbance of was measured at 535 nm. TBARS concentrations	290	
	of the samples were calculated using the extinction co-efficient of	291	
	156,000 M ⁻¹ cm ⁻¹ .	292	

293 2.17. PCR Amplification and mtDNA sequencing

294 The complete mtDNA was amplified from total DNA in 24 overlapping
 295 800–1000-bp-long PCR fragments. Primers were carefully designed using
 296 the revised human mtDNA Cambridge reference sequence (www.mitomap.org/mitoseq.html).
 297

298 The PCR fragments were sequenced in both strands in an
 299 ABI 3730 (Applied Biosystems; www.appliedbiosystems.com;
 300 Foster City, CA) sequencer using a BigDye v3.1 sequencing kit
 301 (Applied Biosystems; www.appliedbiosystems.com; Foster City,
 302 CA). Assembly and identification of variations in the mtDNA were

carried out using the Staden package. For this purpose the revised
 human mtDNA Cambridge reference sequence (www.mitomap.org/mitoseq.html)
 was used. The whole process was carried out at
 Secugen (Madrid, Spain).
 306

2.18. Analysis of apoptosis and viable cells

Viable cells were determined from their normal cell and nuclear
 morphology and exclusion of propidium iodide. In each case 10 random
 fields and more than 500 cells were counted.
 308
 309
 310




Fig. 1. Mitochondrial dysfunction in skin fibroblasts from FM patients. (A) Mitochondrial enzymatic activities were determined as described in [Material and methods](#). Results (mean \pm SD) are expressed in U/CS (units per citrate synthase). (B) Protein expression levels of mitochondrial subunits of complex I, II, III and complex IV. (C) Protein levels were determined by densitometric analysis (IOD, integrated optical intensity) of three different Western blots and normalized to GADPH signal, using fibroblasts from three representative FM patients, compared with a pool of fibroblasts from 5 healthy age- and sex-matched control subjects. * $P < 0.001$; ** $P < 0.01$; *** $P < 0.05$ between control and FM patients.




Fig. 2. Abnormalities in various aspects of bioenergetic function of mitochondria. Oxygen consumption rate (OCR) in cells from control and FM patients. (A) OCR was monitored using the Seahorse XF-24 Extracellular Flux Analyzer with the sequential injection of oligomycin (1 μ g/mL), 2,4-DNP (100 μ M), rotenone (1 μ M) at the indicated time point (B) The basal OCR was markedly affected in cells from FM compared to control. (C) The spare respiratory capacity (SRC) of FM fibroblasts showed a significant decrease with respect to control fibroblasts. (D) CoQ₁₀ levels in control and FM cells. (E) mtDNA copy number was measured by RT-PCR as described in [Material and methods](#). (F and G) mtDNA imaging by PicoGreen staining and quantification of PicoGreen foci in control and FM fibroblasts. For the control cells, data are the means \pm SD for experiments performed on two different control cell lines. Data represent the mean \pm SD of three separate experiments. Bar = 15 μ m. * P < 0.001; ** P < 0.01 between control and FM patients.

311 2.19. Statistical analysis

312 Data in figures is given as mean \pm SD. Data between different groups
 313 were analyzed statistically by using ANOVA on Ranks with Sigma Plot
 314 and Sigma Stat statistical software (SPSS for Windows, 19, 2010, SPSS
 315 Inc. Chicago, IL, USA). For cell-culture studies, Student's t test was used
 316 for data analyses. A value of $P < 0.05$ was considered significant.

3. Results

317

3.1. Mitochondrial metabolism

318

319 As AMPK signaling has been previously reported to be altered in BMCs
 320 from FM patients [9], we have next studied the role of AMPK in FM path-
 321 ophysiology using isolated fibroblasts from three representative FM




Fig. 3. Oxidative stress and oxidative damage levels in fibroblasts from FM patients. (A) Mitochondrial ROS production was analyzed in BMCs from control and FM patients by flow cytometry as described in Material and Methods. (B) Quantification of lipid peroxidation in control and FM fibroblasts. Data represent the oxidized lipid/reduced lipid ratio. Data represent the mean \pm SD of three separate experiments. * $P < 0.001$, ^a $P < 0.01$ between control and FM patients. (C) Protein expression levels of 8-oxoguanine glycosylase (OGG-1, a DNA glycosylase enzyme responsible for the excision of 7,8-dihydro-8-oxoguanine (8-oxoG)). (D) Mitochondrial ROS generation in fibroblasts cultured for 72 h in normal growth medium prior to analysis. MitoSOX Red staining revealed increased superoxide anion. MitoSOX Red colocalized with subunit II of cytochrome c oxidase (COX II) in merged images, indicating that superoxide anion production was mainly in mitochondria. (E) Lipid peroxidation in control and FM fibroblasts using C11-Bodipy staining. Red fluorescence represents non-oxidized lipids, and green fluorescence represents oxidized lipids. Scale bar 30 μ m.

322 patients. FM fibroblasts displayed a significant reduction in the activities
 323 of mitochondrial respiratory enzymes compared to control fibroblasts
 324 (Fig. 1A). Mitochondrial protein expression levels correlated with the de-
 325 pressed activities found in respiratory enzymes (Fig. 1B). Next, we inves-
 326 tigated mitochondrial function by measuring the OCR values in control
 327 and FM fibroblasts, exposed sequentially to each of four modulators of
 328 oxidative phosphorylation (OXPHOS): oligomycin (an inhibitor of F1Fo-
 329 ATPase or complex V), 2,4-DNP (uncoupling of the OXPHOS electron
 330 transport chain) and antimycin/rotenone (complex I and III inhibitors re-
 331 spectively) (Fig. 2A). The basal OCR was markedly affected in fibroblasts
 332 from FM patients compared to controls (Fig. 2B). The spare respiratory
 333 capacity (SRC) of cells was obtained by calculating the mean of OCR
 334 values after injection of 2,4-DNP minus the basal respiration and could
 335 be used as an indicator of how close a cell is operating to its bioenergetic
 336 limit. Fibroblasts from FM patients showed a significant decrease of SRC
 337 compared to control cells (Fig. 2C). Furthermore, similarly to what was
 338 previously found in BMCs [8], FM fibroblasts also showed decreased
 339 CoQ₁₀ levels when compared to controls (Fig. 2D). CoQ₁₀ content of fibro-
 340 blasts from patient 1 was reduced by 70%, from patient 2 by 78% and from
 341 patient 3 by 82%. FM fibroblasts also had a smaller number of mitochon-
 342 dria; we measured mtDNA content and compared it with control values.
 343 Results showed that mtDNA content was 30–50% lower in fibroblasts
 344 from FM (Fig. 2E). This finding was further confirmed by visualizing the
 345 number of mtDNA nucleoids per cell using PicoGreen staining and fluo-
 346 rescence microscopy. Mitochondrial nucleoids were significantly reduced
 347 in FM fibroblasts (Figs. 2F and G).

348 Since mitochondrial respiratory chain defects are usually associated
 349 with mtDNA mutations or deletions, we next sequenced the complete
 350 mtDNA from FM patients. Sequence analysis did not show any impor-
 351 tant alterations as mutations or deletions which could justify the mito-
 352 chondrial defects. We only found mitochondrial polymorphisms which
 353 are also observed in control fibroblasts (Table S1).

3.2. AMPK is implicated in oxidative stress response in FM

354

Mitochondrial superoxide production was significantly increased in
 355 FM fibroblasts compared to controls ($P < 0.001$), accompanied by high
 356 levels of lipid peroxidation (Figs. 3A, B, D and E). To confirm these
 357 results, the expression of an additional oxidative stress marker such as
 358 8-oxoguanine glycosylase (OGG1) was also determined. FM fibroblasts
 359 showed high levels of OGG1 (Fig. 3C).
 360

As AMPK induces PGC-1 α phosphorylation which leads to increased
 361 antioxidant enzymes expression levels and mitochondrial biogenesis,
 362 we analyzed AMPK protein expression levels and activation in FM
 363 fibroblasts. Results showed low expression levels of active phosphory-
 364 lated AMPK, PGC-1 α and MnSOD (Fig. 4A), suggesting that AMPK-
 365 dependent activation of PGC-1 α was indeed impaired in FM fibroblasts.
 366 As reduced antioxidant enzyme levels have been previously described
 367 in FM [5,6,11], we next investigated the response to moderate oxidative
 368 stress induced by exogenous addition of H₂O₂ in FM fibroblasts. Incuba-
 369 tion of FM fibroblasts with H₂O₂ failed to activate AMPK and PGC-1 α
 370 and to increase MnSOD expression levels (Fig. 4A). As a consequence
 371 of an impaired defensive response to oxidative stress, cell death
 372 increased in FM fibroblasts treated with H₂O₂ (Fig. 4B).
 373

Under oxidative stress condition, AMPK was found to lead to an
 374 increase in the NADPH generation [14]. However, as FM fibroblasts
 375 had reduced activity of phosphorylated AMPK, we found low levels of
 376 NADPH. Interestingly, metformin, an AMP mimetic that directly acti-
 377 vates AMPK, induced an increase of NADPH levels and the activity of
 378 SOD and catalase (Figs. 5A–C).
 379

FM fibroblasts under moderate oxidative stress conditions mediated
 380 by H₂O₂ treatment or induction of AMPK by metformin showed PGC-
 381 1 α activation (Fig. 5D) which increased protection against H₂O₂
 382 exposure and reduced cell death (Fig. 5E). These results suggest that
 383 the induction of AMPK phosphorylation could to be an interesting
 384




Fig. 4. Comparison of oxidative stress levels and metabolic response to H₂O₂ treatment of skin fibroblasts between FM patients and healthy subjects. (A) Protein expression levels of phosphorylated AMPK, PGC-1 α , and MnSOD after incubation with 100 mM H₂O₂ for 48 h. Protein levels were determined by densitometric analysis (IOD, integrated optical intensity) of three different Western blots and normalized to GAPDH signal. * $P < 0.001$ between control and FM patients. (B) Percentage of apoptosis in control and FM fibroblasts after incubation with 100 mM H₂O₂ for 48 h. * $P < 0.001$ between control and FM patients.




Fig. 5. Effects of metformin treatment on antioxidant defense and oxidative stress response of fibroblasts from FM patients. (A, B and C) NADPH levels and antioxidant enzymes SOD and catalase (CAT) activities in FM fibroblasts treated with metformin (Met). * $P < 0.001$ and ** $P < 0.05$ between control and control with Met. ^a $P < 0.001$ and ^{aa} $P < 0.005$ between FM and control. [#] $P < 0.001$ between FM and FM with Met. (D) Levels of phosphorylated PGC- α in FM fibroblasts after 100 mM H₂O₂ and 2 mM Met treatments for 48 h (representative subset is shown). (E) Percentage of apoptosis in control and FM fibroblasts after incubation with 100 mM H₂O₂ and 2 mM Met for 48 h. * $P < 0.001$ between control and FM patients and between H₂O₂ and H₂O₂ + Met.

therapeutic approach in FM. Given that it has been speculated that the beneficial effects of caloric restriction (CR) could be mediated by AMPK [3], CR could be a promising method to alleviate oxidative damage in FM. Taken into account the possible role of AMPK in FM pathophysiology and the results with metformin treatment, we next studied the implication of AMPK in the protective effect of CR on FM fibroblasts. Thus, we performed an experiment with a mouse model of CR. Several mice were fed with a normal diet and with CR for one month. Mice submitted to the CR diet for one month developed a marked analgesia

when compared with *ad libitum* (AL) fed mice (Fig. 6A) accompanied by AMPK phosphorylation (Fig. 6B) and reduced levels of serum oxidative stress (Fig. 6C). To determine the potential effect of improvement of AMPK by CR, fibroblasts from FM patients were cultured with serum from AL and CR mice, and cell growth, ATP and mitochondrial mass were assessed. Serum from CR mice improved cell growth in controls and FM fibroblasts (Fig. 6D), accompanied by an increase in ATP levels and mitochondrial mass (determined by increased citrate synthase activity) and cell morphology normalization (Figs. 6E–G).




Fig. 6. Effects of caloric restriction on bioenergetics function of mice and skin fibroblasts from FM patients. (A) Evolution of pain sensitivity in *ad libitum* (AL) and caloric restriction (CR) mice evaluated in the hot plate test at 55 °C. (B) Phosphorylation of AMPK after CR. (C) Oxidative stress in serum evaluated by TBARS levels. (D) Cell growth with AL and CR serum determined in healthy and FM fibroblasts. (E) Morphological changes of fibroblasts incubated with FBS or serum from AL or CR mice. (F) ATP levels in control and FM fibroblasts. (G) Mitochondrial mass determined by measuring citrate synthase levels and cytochrome c levels by immunofluorescence in control and FM fibroblasts. Data represents the means \pm SD of three separate experiments. * $P < 0.001$ AL or CR; ** $P < 0.01$ between AL or CR in control fibroblasts.

403 4. Discussion

404 Despite decades of intense research, the basic pathophysiological
 405 mechanisms of FM still remain elusive. Several important pathophysio-
 406 logical processes in FM onset and development have been described:
 407 oxidative stress, mitochondrial dysfunction, bioenergetic alterations
 408 and inflammation processes are only some of the most important mech-
 409 anisms that have been postulated [5–11]. AMPK has been reported to
 410 play a master regulatory role in all these cellular processes and its dys-
 411 regulation has been described in several other diseases [15]. Recently,
 412 we have reported alterations in AMPK signaling in BMCs from FM pa-
 413 tients. However, the role of AMPK in FM remains unknown. In this
 414 study, we found a marked mitochondrial dysfunction in fibroblasts de-
 415 rived from 3 FM patients. It is interesting to remark that until now, all
 416 the studies in FM have explored the pathophysiological processes only
 417 in biological samples isolated directly from patients, e.g. BMCs, platelets,
 418 serum, plasma, saliva, muscle. In this work we have used human dermal
 419 fibroblasts that have a long track record of utility in mitochondrial

disease biochemistry and molecular studies [1]. Skin fibroblasts repre- 420
 sent a useful biological model in which defined mutations and the 421
 cumulative cellular damage can be examined. We found reduced mito- 422
 chondrial chain enzymatic activities and proteins, CoQ₁₀ levels, mito- 423
 chondrial mass and ATP levels, accompanied by increased oxidative 424
 damage. We found no specific mutation after mtDNA sequencing; how- 425
 ever, we cannot rule out the presence of mutations in nDNA or potential 426
 mtDNA mutations in other patients not included in this study. 427

Moreover, we observed reduced levels of phosphorylated PGC-1 α 428
 accompanied by low levels of antioxidant MnSOD and impaired oxida- 429
 tive stress response which are protective mechanisms controlled by 430
 AMPK. Furthermore, reduced levels of active phosphorylated AMPK 431
 were observed in FM fibroblasts. These data are interesting because 432
 AMPK has been involved in the control of peripheral sensitization of 433
 nociceptors, providing evidence of AMPK activation as a novel treat- 434
 ment avenue for acute and chronic pain states [16]. In addition, the 435
 exposition of fibroblasts to moderate oxidative stress, as induced by 436
 exogenously added H₂O₂, fails to up-regulate AMPK, PGC-1 α and 437

antioxidant enzymes. Concerning this, AMPK has been deeply involved in the regulation of oxidative stress and mitochondrial dysfunction [17–19]. In this sense, AMPK phosphorylation by metformin treatment induced activation of PGC-1 α accompanied by increased antioxidant enzyme activities and, as a consequence, protection of FM fibroblasts against stress exposure. PGC-1 α is a key player in the ROS-induced mitochondrial biogenesis, along with the NRF-1 and the mitochondrial transcription factor Tfam [20]. According to our data, metformin could induce PGC-1 α activation by AMPK phosphorylation. Furthermore, PGC-1 α has a key role in the antioxidant enzymes biosynthesis, and its genetic deletion has shown an inhibitory effect in SOD2 and catalase expression levels [4,20]. Furthermore, it has been shown that PGC-1 α induction by phosphorylation of AMPK increases SOD2 and catalase expression levels [21]. Our data show that PGC-1 α activation by metformin induces increased mitochondrial biogenesis and antioxidant enzymes expression levels, and, as a consequence, a more physiological response to oxidative stress. A chronic exposure to oxidative stress and dysregulation of the stress response are accepted causative factors involved in the pathophysiology of FM [11,22–24]. Our results could represent the basis for a valuable new therapeutic target/strategy. We found in FM fibroblasts: (i) a lack of AMPK phosphorylation and (ii) restoration of its phosphorylation by AMPK activators, such as metformin. These findings suggest that AMPK plays a central role in FM pathophysiology and stress response. Identification of AMPK as a regulating factor in FM would have implications for patient management and treatment. We can hypothesize that the loss of sensitivity of AMPK activation is responsible for increased oxidative stress and impaired bioenergetics in FM patients. Furthermore, other metabolic events have been related with AMPK down-regulation. Reduced AMPK activity has been found in obesity or metabolic syndrome [3], both reported to be implicated in FM [25,26]. AMPK dysfunction seems to explain many of the pathophysiological alterations found in FM. In this sense, activation of AMPK with other activators having similar effects to metformin must induce similar beneficial effects. To investigate whether AMPK could be responsible for the ability of CR to improve the cells of FM patients, we used an *in vitro* cell culture model that recapitulates key *in vivo* proliferative and phenotypic features of CR [27]. In this model, cells from patients were cultured in the presence of serum from caloric restricted mice resulting in an important improvement in FM fibroblasts alterations. Future research should be focused on studying the significance of AMPK in FM etiology and as a therapeutic target. Furthermore, an important challenge in FM is the moderate effectiveness of pharmacological therapies; in this sense, AMPK activators, such as AICAR, metformin, CoQ₁₀, resveratrol, CR or physical activity, can provide new therapeutic opportunities [3]. As not all patients have a mitochondrial dysfunction, our results could help to characterize a subgroup of patients in which mitochondrial target treatment could be the most appropriate strategy. In this sense, mitochondrial protector drugs or mitochondrial biogenesis activators may also be considered as new possible therapeutic approach in FM. Nevertheless, more research is needed in order to establish a possible primary causation link between AMPK and FM.

The results described in this article could serve as a new way of designing experiments to better understand the influence of oxidative stress on the development of FM and generate new therapeutic strategies.

Abbreviations

AL	<i>ad libitum</i>
CAT	catalase
CoQ ₁₀	Coenzyme Q ₁₀
CR	caloric restriction
FBS	fetal bovine serum
FM	Fibromyalgia
HPLC	high-performance liquid chromatography
Met	metformin
OCR	oxygen consumption rate

OGG1	8-oxoguanine glycosylase	502
PGC-1 α	peroxisomal proliferator activator receptor γ co-activator 1 α	503
NRF1	nuclear respiratory factor-1	504
ROS	reactive oxygen species	505
SOD	superoxide dismutase	506
TBARS	thiobarbituric acid reactive substances	508

Author disclosure statement

All the Authors declare that no conflict of interest exists for any of them. 510 511

Author contributions

E.A.G. and M.D.C. conceived of the study and wrote the manuscript. 513
A.M.C., E.A.G., F.M.A., and DC. performed mouse experiments. E.A.G., 514
J.G.M., J.M.A.S., F.G. P.B. and J.A.S.A. performed cell culture experiments. 515
J.A.S.A. conducted patient evaluations and skin biopsies isolation. 516
All authors analyzed and discussed the data and commented on the 517
manuscript. 518

Acknowledgments

This work has been supported by Federación Andaluza de 520
Fibromialgia y Fatiga Crónica (ALBA Andalucía) and Grupo de 521
Investigación Junta de Andalucía CTS113. Authors are indebted 522
with Ms Monica Glebocki for extensive editing of the manuscript. 523

Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.bbadis.2015.03.005>. 525 526

References

- [1] R.H. Haas, S. Parikh, M.J. Falk, R. Saneto, N.I. Wolf, N. Darin, L.J. Wong, B.H. Cohen, R.K. Naviaux, The in-depth evaluation of suspected mitochondrial disease, *Mol. Genet. Metab.* 94 (2008) 16–37. 528 529 530
- [2] J.F. Turrens, Mitochondrial formation of reactive oxygen species, *J. Physiol.* 552 (2003) 335–441. 531 532
- [3] G.R. Steinberg, B.E. Kemp, AMPK in health and disease, *Physiol. Rev.* 89 (2009) 1025–1078. 533 534
- [4] S.L. Colombo, S. Moncada, AMPK α 1 regulates the antioxidant status of vascular endothelial cells, *Biochem. J.* 421 (2009) 163–169. 535 536
- [5] O. Altindag, H. Celik, Total antioxidant capacity and the severity of the pain in patients with fibromyalgia, *Redox Rep.* 11 (2006) 131–135. 537 538
- [6] S. Bagis, L. Tamer, G. Sahin, R. Bilgin, H. Guler, B. Ercan, C. Erdogan, Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? *Rheumatol. Int.* 25 (2005) 188–190. 539 540 541
- [7] S. Ozgocmen, H. Ozyurt, S. Sogut, O. Akyol, Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide, *Rheumatol. Int.* 26 (2006) 585–597. 542 543 544
- [8] M.D. Cordero, E. Díaz-Parrado, A.M. Carrión, S. Alfonsi, J.A. Sánchez-Alcazar, P. Bullón, M. Battino, M. de Miguel, Is inflammation a mitochondrial dysfunction-dependent event in fibromyalgia? *Antioxid. Redox Signal.* 18 (2013) 800–807. 545 546 547
- [9] M.D. Cordero, E. Alcocer-Gómez, M. de Miguel, O. Culic, A.M. Carrión, J.M. Alvarez-Suarez, P. Bullón, M. Battino, A. Fernández-Rodríguez, J.A. Sánchez-Alcazar, Can coenzyme Q10 improve clinical and molecular parameter in fibromyalgia? *Antioxid. Redox Signal.* 19 (2013) 1356–1361. 548 549 550
- [10] L. Bazzichi, G. Giannaccini, L. Betti, L. Fabbrini, L. Schmid, L. Palego, C. Giacomelli, A. Rossi, L. Giusti, F. De Feo, T. Giuliano, G. Mascia, S. Bombardieri, A. Lucacchini, ATP, calcium and magnesium levels in platelets of patients with primary fibromyalgia, *Clin. Biochem.* 41 (2008) 1084–1090. 551 552 553 554 555
- [11] M. Neyal, F. Yimenicioglu, A. Aydeniz, A. Taskin, S. Saglam, M. Cekmen, A. Neyal, S. Gursoy, O. Erel, A. Balat, Plasma nitrite levels, total antioxidant status, total oxidant status, and oxidative stress index in patients with tension-type headache and fibromyalgia, *Clin. Neurol. Neurosurg.* 115 (2013) 736–740. 556 557 558 559
- [12] H. Aebi, Catalase *in vitro*, *Methods Enzymol.* 105 (1984) 121–126. 560
- [13] P. Kakkur, B. Das, P.N. Viswanathan, A modified spectrophotometric assay of superoxide dismutase, *Indian J. Biochem. Biophys.* 21 (1984) 130–132. 561 562
- [14] D.G. Hardie, F.A. Ross, S.A. Hawley, AMPK: a nutrient and energy sensor that maintains energy homeostasis, *Nat. Rev. Mol. Cell Biol.* 13 (2012) 251–262. 563 564
- [15] S.B. Wu, Y.H. Wei, AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: implication of the cell survival in mitochondrial diseases, *Biochim. Biophys. Acta* 1822 (2012) 233–247. 565 566 567

- 568 [16] O.K. Melemedjian, M.N. Asiedu, D.V. Tillu, R. Sanoja, J. Yan, A. Lark, A. Khoutorsky, J.
569 Johnson, K.A. Peebles, T. Lepow, N. Sonenberg, G. Dussor, T.J. Price, Targeting aden-
570 osine monophosphate-activated protein kinase (AMPK) in preclinical models
571 reveals a potential mechanism for the treatment of neuropathic pain, *Mol. Pain* 7
572 (2011) 70.
- 573 [17] K. Cao, A. Zheng, J. Xu, H. Li, J. Liu, Y. Peng, J. Long, X. Zou, Y. Li, C. Chen, J. Liu, Z. Feng,
574 AMPK activation prevents prenatal stress-induced cognitive impairment: modulation
575 of mitochondrial content and oxidative stress, *Free Radic. Biol. Med.* 75 (2014)
576 156–166.
- 577 [18] S.B. Wu, Y.T. Wu, T.P. Wu, Y.H. Wei, Role of AMPK-mediated adaptive responses in
578 human cells with mitochondrial dysfunction to oxidative stress, *Biochim. Biophys.*
579 *Acta* 1840 (2014) 1331–1344.
- 580 [19] K. Takeuchi, Y. Morizane, C. Kamami-Levy, J. Suzuki, M. Kayama, W. Cai, J.W. Miller,
581 D.G. Vavvas, AMP-dependent kinase inhibits oxidative stress-induced caveolin-1
582 phosphorylation and endocytosis by suppressing the dissociation between c-Abl
583 and Prdx1 proteins in endothelial cells, *J. Biol. Chem.* 288 (2013) 20581–20591.
- 584 [20] Z. Lu, X. Xu, X. Hu, J. Fassett, G. Zhu, Y. Tao, J. Li, Y. Huang, P. Zhang, B. Zhao, Y. Chen,
585 PGC-1 alpha regulates expression of myocardial mitochondrial antioxidants and
myocardial oxidative stress after chronic systolic overload, *Antioxid. Redox Signal.* 13
13 (2010) 1011–1022.
- [21] D. Marmolino, M. Manto, F. Acquaviva, P. Vergara, A. Ravella, A. Monticelli, M.
Pandolfo, PGC-1alpha down-regulation affects the antioxidant response in Friedreich's
ataxia, *PLoS One* 5 (2010) e10025.
- [22] D.J. Clauw, Fibromyalgia: a clinical review, *JAMA* 311 (2014) 1547–1555.
- [23] M.E. Bote, J.J. García, M.D. Hinchado, E. Ortega, Inflammatory/stress feedback dysreg-
ulation in women with fibromyalgia, *Neuroimmunomodulation* 19 (2012) 343–351.
- [24] R. Alok, S.K. Das, G.G. Agarwal, L. Salwahan, R. Srivastava, Relationship of severity of
depression, anxiety and stress with severity of fibromyalgia, *Clin. Exp. Rheumatol.*
29 (2011) S70–S72.
- [25] L. Arranz, M.A. Canela, M. Rafecas, Relationship between body mass index, fat mass
and lean mass with SF-36 quality of life scores in a group of fibromyalgia patients,
Rheumatol. Int. 32 (2012) 3605–3611.
- [26] B.L. Loevinger, D. Muller, C. Alonso, C.L. Coe, Metabolic syndrome in women with
chronic pain, *Metabolism* 56 (2007) 87–93.
- [27] R. de Cabo, S. Fürer-Galbán, R.M. Anson, C. Gilman, M. Gorospe, M.A. Lane, An
in vitro model of caloric restriction, *Exp. Gerontol.* 38 (2003) 631–639.

604

UNCORRECTED PROOF